Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AGI-1067: Completed Phase III enrollment

AGIX completed enrollment of 999 patients in the double-blind, international Phase III ANDES

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE